|
|
Opioids Linked to Increased Dementia Risk
June 6, 2022
 |
NA recently published Israeli study examined the association between opioid use and the risk of incident dementia in old age based on a nationally-representative cohort. The researchers examined the relationship between opioid exposure and dementia in people who…... |
|
 Continue reading (Members only)
|
|
FDA Authorizes Marketing for New Test to Improve Diagnosis of Alzheimer’s Disease
May 9, 2022
 |
The U.S. Food and Drug Administration (FDA) approved marketing authorizationnfor anst in vitro diagnostic test for the early detection of amyloid plaques, one of the pathological hallmarks associated with Alzheimer's adises. The test is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline... |
|
Continue reading (Members only)
|
|
Impact of Neuropsychiatric Symptoms in Alzheimer’s Disease
March 4, 2022
 |
Neuropsychiatric symptoms, including depression, apathy, and anxiety, are common among individuals with Alzheimer’s dementia. It is not yet clear the relationship among NPS, cognitive symptoms, and Alzheimer’s dementia neuropathology (which includes amyloid beta deposits, neurofibrillary tangles composed of hyperphosphorylated tau, and neurodegeneration). In this article... |
|
Continue reading
|
|
ADHD and Alzheimer’s Disease Across Generations
September 25, 2021
 |
Due to previous conflicting results regarding the association between attention-deficit hyperactivity disorder (ADHD) and Alzheimer’s disease (AD), a recent nationwide cohort study evaluated their link across generations. Index persons (N=2,132,929) born in Sweden were linked to their biological relatives: 4,246,182 index person-parent pairs.... |
|
Continue reading (Members only)
|
|
|
|
FDA Grants Accelerated Approval for Alzheimer’s Drug
June 22, 2021
|
It has been 2 decades since pre-clinical research on passive immunotherapy for Alzheimer’s disease began and the effort of thousands of researchers seems to finally be paying off. Aducanumab, a passive immunotherapy consisting of anti-amyloid human monoclonal antibodies, has been shown to reduce brain amyloid burden and... |
|
Continue reading (Members only)
|
|
Short Sleep Tied to Increased Dementia Risk
May 4, 2021
 |
In a recent study, the association between sleep dysregulation and dementia was examined. Data from 7,959 participants of the Whitehall II study was analyzed for sleep duration and the incidence of dementia, using a 25-year follow-up. A total of... |
|
Continue reading (Members only)
|
|
Psychotropic Polypharmacy Prevalent in Patients With Dementia
March 25, 2021
 |
Dementia is increasingly prevalent as the population ages. In addition to memory deficits, patients with dementia often exhibit other neuropsychiatric symptoms that can be disturbing to caregivers and increase the likelihood of institutionalization. It is therefore not uncommon for patients with dementia to be prescribed psychotropic agents despite... |
|
Continue reading (Members only)
|
|
Apathy an Early Marker of Frontotemporal Dementia
February 1, 2021
 |
Frontotemporal dementia is a disorder resulting from accumulation of pathological proteins such as phosphorylated tau and transactive response DNA binding protein of 43 kDA in the brain. Mutations in various genes, including microtubule associated protein tau... |
|
Continue reading (Members only)
|
|